NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading PAVM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a high risk profile, but it operates in a sector that is experiencing favorable momentum.
The market appears to price PAVM as a cheap option within its sector, reflecting low expectations due to its recent weak financial performance. Investors seem to be cautious, given the company's losses and cash burn.
Management is behind on advancing clinical development and maintaining capital discipline, which could continue to impact performance negatively. The recent financial results have been weak, and there is a significant risk of missing future earnings expectations.
The long-term thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT, as well as potential interest rate cuts by the Fed. These factors could either support or hinder PAVM's growth prospects.
Over the next 1 to 3 years, PAVM's performance will largely depend on external sector dynamics and internal management execution. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses noted. The company remains under pressure due to weak recent financial performance. Management is still behind on commitments, which is a concern.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if cash burn and operating losses are improving. Investors will react to any signs of progress.
Confirms:Earnings report shows smaller operating losses. They were -$8.0M in Q1.
Disproves:Operating losses get worse or stay the same. This is compared to past quarters.
Why it matters: Earnings results will show if the company can improve its financial performance. A strong report may boost investor confidence.
Confirms one read:Q2 earnings beat what analysts expected. Revenue went up and losses went down.
Confirms the other:Q2 earnings miss expectations again. This shows ongoing financial problems.
Why it matters: Managing cash burn is key for survival. Improvement may show better financial health.
Confirms:Operating losses drop a lot. This shows better cash flow management.
Disproves:Operating losses worsen or cash burn remains high.
Why it matters: Managing cash burn is key for survival. Improvements show better financial health.
Confirms:Management says operating losses fell to less than -$4M.
Disproves:Operating losses increase beyond -$8M in Q2.
Why it matters: The FDA submission is a key step for Veris Health's product, impacting future revenue.
Confirms:Veris Health says it has filed with the FDA for the implantable monitor.
Disproves:Delays in the FDA submission process are reported.
